Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

MLA

Luan, Xin, et al. “Reappraisal of Anticancer Nanomedicine Design Criteria in Three Types of Preclinical Cancer Models for Better Clinical Translation.” Biomaterials, vol. 275, Aug. 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.biomaterials.2021.120910.

APA

Luan, X., Yuan, H., Song, Y., Hu, H., Wen, B., He, M., Zhang, H., Li, Y., Li, F., Shu, P., Burnett, J. P., Truchan, N., Palmisano, M., Pai, M. P., Zhou, S., Gao, W., & Sun, D. (2021). Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 275, N.PAG. https://doi.org/10.1016/j.biomaterials.2021.120910

Chicago

Luan, Xin, Hebao Yuan, Yudong Song, Hongxiang Hu, Bo Wen, Miao He, Huixia Zhang, et al. 2021. “Reappraisal of Anticancer Nanomedicine Design Criteria in Three Types of Preclinical Cancer Models for Better Clinical Translation.” Biomaterials 275 (August): N.PAG. doi:10.1016/j.biomaterials.2021.120910.